Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) Meeting Abstract
| Authors: | Garcia-Manero, G.; Yang, A. S.; Klimek, V.; Luger, S.; Newsome, W. M.; Berman, N.; Patterson, T.; Maroun, C.; Li, Z.; Ward, R.; Martell, R. |
| Abstract Title: | Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) |
| Meeting Title: | 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 25 |
| Issue: | 18 Suppl. |
| Meeting Dates: | 2007 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2007-06-20 |
| Start Page: | 372s |
| Language: | English |
| ACCESSION: | WOS:000455043701668 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2007.25.18_suppl.7062 |
| Notes: | Meeting Abstract: 7062 -- Source: Wos |
